Radiopharm Theranostics Says its Proprietary Radiotracer Detected Brain Metastases in New Clinical Study; Shares Down 4%

MT Newswires Live

Feb 10, 2025

Radiopharm Theranostics (ASX:RAD) said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.

A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.

The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.

The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.

The firm's shares fell 4% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510500577"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510500577\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510500577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 11:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510500577","market":"fut","top_or_hot":-1,"title":"Radiopharm Theranostics Says its Proprietary Radiotracer Detected Brain Metastases in New Clinical Study; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> Radiopharm Theranostics (ASX:RAD) said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.</p><p>A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.</p><p>The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.</p><p>The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.</p><p>The firm's shares fell 4% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Radiopharm Theranostics Says its Proprietary Radiotracer Detected Brain Metastases in New Clinical Study; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRadiopharm Theranostics Says its Proprietary Radiotracer Detected Brain Metastases in New Clinical Study; Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-10 11:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Radiopharm Theranostics (ASX:RAD) said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.</p><p>A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.</p><p>The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.</p><p>The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.</p><p>The firm's shares fell 4% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAD.AU","symbol_name":"RADIOPHARM THERANOSTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510500577","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510500577","pubTimestamp":1739157643,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Radiopharm Theranostics  said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.The firm's shares fell 4% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAD.AU":"RADIOPHARM THERANOSTICS LTD","BK7067":"生物科技"},"translate_title":"Radiopharm Theranostics表示，其专有的放射性示踪剂在新的临床研究中检测到了脑转移；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAD.AU":0.9},"content_text":"Radiopharm Theranostics (ASX:RAD) said that a recently published study reported a methodology for detecting brain metastases using its proprietary radiotracer 18F-RAD101, according to a Monday Australian bourse filing.A study published in the European Journal of Nuclear Medicine and Molecular Imaging investigated the imaging characteristics of brain metastases in 12 patients with no prior brain radiotherapy and 10 patients who had previously been treated with brain radiation.The use of the radiotracer with Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging detected all brain metastases, regardless of the tumor of origin, with a high tumor-to-background ratio, the filing said.The biopharmaceuticals firm's phase 2b clinical trial to evaluate the diagnostic performance of the radiotracer in patients with suspected recurrent brain metastasis from solid tumors of different origins is currently recruiting in the US.The firm's shares fell 4% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}